<- Go Home
Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Market Cap
$36.9M
Volume
24.1K
Cash and Equivalents
$1.2M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$9.99
52 Week Low
$1.98
Dividend
N/A
Price / Book Value
10.26
Price / Earnings
-4.35
Price / Tangible Book Value
10.26
Enterprise Value
$32.7M
Enterprise Value / EBITDA
-6.69
Operating Income
-$4.9M
Return on Equity
2614.86%
Return on Assets
-107.15
Cash and Short Term Investments
$4.3M
Debt
$118.0K
Equity
$2.8M
Revenue
N/A
Unlevered FCF
-$3.0M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium